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With an estimated 1.1 million men worldwide diagnosed with prostate cancer yearly,
effective and more specific biomarkers for early diagnosis could lead to better patient
outcome. As such, novel genetic markers are sought for this purpose. The tribbles
homologue 1 gene (TRIB1) has recently shown to have a role in prostate tumorigenesis
and data-mining of prostate cancer expression data confirmed clinical significance of
TRIB1 in prostate cancer. For the first time, a polymorphic microsatellite in this gene
was studied for its potential association with prostate cancer risk and aggressiveness.
Genomic DNA was extracted from a cohort of 1,152 prostate cancer patients and
1,196 cancer-free controls and the TTTTG-TRIB1 microsatellite was genotyped. The
socio-demographic and clinical characteristics were analyzed using the non-parametric
t-test and two-way ANOVA. Association of the TTTTG-TRIB1 microsatellite and prostate
cancer risk and aggressiveness were analyzed by binary logistic regression and
confirmed by bootstrapping. Total and prostate cancer mortality was analyzed using
the Kaplan Meier test. Genotype and allele correlation with TRIB1 mRNA levels was
analyzed using the non-parametric Kolmogorov–Smirnov test. To predict the effect that
the TTTTG-TRIB1 polymorphisms had on the mRNA structure, the in silico RNA folding
predictor tool, mfold, was used. By analyzing the publicly available data, we confirmed a
significant over-expression of TRIB1 in prostate cancer compared to other cancer types,
and an over-expression in prostate cancerous tissue compared to adjacent benign.
Three alleles (three–five repeats) were observed for TTTTG-TRIB1. The three-repeat
allele was associated with prostate cancer risk at the allele (OR = 1.16; P = 0.044)
and genotypic levels (OR = 1.70; P = 0.006) and this association was age-independent.
The four-repeat allele was inversely associated with prosatet cancer risk (OR = 0.57;
P < 0.0001). TRIB1 expression was upregulated in tumors when compared to adjacent
cancer-free tissue but was not allele specific. In silico analysis suggested that the
TTTTG-TRIB1 alleles may alter TRIB1 mRNA structure. In summary, the three-repeat
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allele was significantly associated with prostate cancer risk, suggesting a biomarker
potential for this microsatellite to predict prostate cancer. Further studies are needed to
elucidate the functional role of this microsatellite in regulating TRIB1 expression, perhaps
by affecting the TRIB1 mRNA structure and stability.
Keywords: short tandem repeats (STRs), microsatellite, tribbles homologue 1 gene (TRIB1), prostate cancer,
biomarker
INTRODUCTION
Australia and New Zealand, followed by North America, were
the countries with the highest prostate cancer incidence in
the developed world in 2012, according to the World Health
Organization (Jemal et al., 2011). In 2016, 18,138 males were
diagnosed with prostate cancer in Australia, accounting for
25.2% of all new male cancer cases and 12.8% of all male
deaths caused by cancer (Welfare Aloha, 2016). In an increasing
aging population, the numbers of newly diagnosed men with
prostate cancer are likely to rise. Despite all the accumulated
knowledge of the disease, the prostate-specific antigen (PSA) test
remains one of the most common methods of screening since its
introduction 30 years ago. However, the PSA test has gathered
criticism for its potential over-diagnosis (Etzioni et al., 2002)
and overtreatment consequences (Howrey et al., 2013). In 2012,
The American Society of Clinical Oncology (Basch et al., 2012)
and the U.S. Preventive Services Task Force (Moyer and U. S.
Preventive Services Task Force, 2012) recommended against its
use as a routine screening test. In this light, new and more specific
biomarkers are needed.
Microsatellites, or short tandem repeats (STRs), are typically
consecutive repeats of 2–5 base pairs (bp) of DNA in the genome.
STRs are attractive biomarkers in human disease due to their
highly polymorphic nature, abundancy, and wide distribution
throughout the genome (Schlotterer, 2004; Willems et al.,
2014). They have been used for high-resolution human genome
mapping (Kong et al., 2002), population studies (Edwards et al.,
1992; Budowle et al., 2002), and associated with up to 40 human
monogenic diseases such as oculopharyngeal muscular dystrophy
(Willems et al., 2014), as well as with more complex diseases such
as cystic fibrosis and asthma (Hefferon et al., 2004; Batra et al.,
2007).
Genome-Wide Association Studies (GWAS) genotype
large cohorts of patients and controls, using high-throughput
screening platforms to identify single-nucleotide polymorphisms
(SNPs) that are associated with prostate cancer. This approach
has been successful in identifying over 150 susceptibility loci
for prostate cancer in a European cohort (Al Olama et al.,
2014; Srinivasan et al., 2016; Schumacher et al., 2018). However,
GWAS conducted to date can explain only up to ∼33% of
prostate cancer heredity (Al Olama et al., 2014). We hypothesize
that some of the missing prostate cancer genetic component
can be explained by other genetic variants such as STRs. We
used existing expression databases and bioinformatics tools that
detect functional STRs lying in differentially expressed genes in
prostate cancer as described previously by us (Lai et al., 2017),
whereby we identified a penta-STR within the 3′UTR of the
tribbles homologue 1 gene (TRIB1): TTTTG-TRIB1. Recent
studies have associated the TRIB1 gene with the development of
several tumors including colorectal (Wang et al., 2017), leukemia
(Yoshida et al., 2013), and hepatocellular (Ye et al., 2017) cancers.
Also, in prostate cancer it has recently shown to have a role in
cancer cell proliferation, survival and tumor growth (Mashima
et al., 2014). Furthermore, independent clinical studies have
reported higher expression of TRIB1 in prostate cancer when
compared to other cancers (Su et al., 2001; Ramaswamy et al.,
2003) and an up-regulation of the TRIB1 gene in prostate cancer
tissue when compared to adjacent cancer-free cells (Liu et al.,
2006; Grasso et al., 2012). However, the mechanisms by which
its expression is upregulated in prostate cancer are not yet
understood (Yu et al., 2004; Taylor et al., 2010; Grasso et al.,
2012; Mashima et al., 2014). Additionally, we and others have
observed a down-regulation of the TTTTG-TRIB1 STR and the
TRIB1 gene (Munkley et al., 2015; Lai et al., 2017) in LNCaP
cells after androgen treatment, supporting a link between TRIB1
and prostate cancer. Interestingly, a recent study has observed
an increase of TRIB1 DNA copies and mRNA levels in breast
cancer patients with a poorer survival outcome and a more
aggressive phenotype in (Gendelman et al., 2017) after regulating
proliferation, apoptosis, and cytokine production. Here, we
undertook the largest genotyping analysis of a microsatellite
repeat in this gene and analyzed its association with prostate
cancer risk, aggressiveness and survival.
MATERIALS AND METHODS
TRIB1 Expression in Cancer
The Oncomine gene mining database (Rhodes et al., 2004) was
used to determine how the TRIB1 gene expression in prostate
cancer compares with other cancers (Figures 1A,B) and to
confirm if its expression was higher in prostate tumor tissue when
compared to non-tumor prostatic tissue (Figures 1C,D). This
mining web-tool extracts differential gene expression data from
microarray analysis which originate from numerous samples
such as cancer physiological fluids and tissues. Clinical and
pathological data is also made available to the user. All the data
presented is normalized and statistically analyzed.
In order to analyze the expression of the TRIB1 gene in
multiple cancer types, two multi-cancer studies were selected.
The selection criteria were based on their number of samples
and data availability for the prostate cancer. In the first study
(Figure 1A) by Su et al. (2001) TRIB1 gene expression data
was available from prostate tumor as well as eight other cancers
(n = 174; bladder, breast, colorectal, kidney, liver, lung, ovarian,
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FIGURE 1 | TRIB1 is overexpressed in prostatate cancer. The Oncomine database showed that TRIB1 was overexpressed in (A) prostate cancer when compared to
eight (n = 174; Su et al., 2001), (B) and four other cancer types (n = 76; Ramaswamy et al., 2003) and in prostate cancer when compared to adjacent cancer-free
tissue with in (C) Grasso et al. (2012) dataset (n = 122) and (D) Liu et al. (2006) dataset (n = 57); BlCa, bladder cancer; BCa, breast cancer; CoCa, colorectal cancer;
KiCa, kidney cancer; LiCa, liver cancer; LuCa, lung cancer; OvCa, ovarian cancer; PaCa, pancreatic cancer; PCa, prostate cancer.
and pancreatic). In the second study (Figure 1B), Ramaswamy
et al. (2003) analyzed the TRIB1 gene expression in prostate
malignant tissue and compared it to four other cancer types
(n = 76; breast, colorectal, lung and ovarian). The arrays used in
the first study were the Human Genome U95A-Av2 Array while
the HumanGeneFL Array, Hu35KsubA Array was used in the
second study.
We then searched for reported differential expression of the
TRIB1 gene in prostate cancer when compared to prostatic
benign tissue. Two studies that reflect this differential expression
were selected for their number of samples available. The first
study selected was carried out by Grasso et al. (2012; Figure 1C),
where a total of 122 samples were analyzed (59 localized prostate
carcinoma, and 28 benign prostate tissue specimens) using the
Agilent Human Genome 44K array. The second selected study
was presented by Liu et al. (2011; Figure 1D), where a total of 57
samples (44 prostate carcinoma and 13 adjacent normal samples)
using the Human Genome U133A Array.
Prostate Cancer Patients and
Cancer-Free Controls
A total of 1,152 prostate patients were analyzed, including 138
men recruited via collaborations with urologists, 347 men from
the QLD node of the Australian Prostate Cancer BioResource
(APCB) and 667 men recruited in collaboration with the Cancer
Council Queensland ProsCan study as detailed in our previous
studies (Batra et al., 2011a; Lose et al., 2012; Eeles et al., 2013).
An extensive medical record for each patient that includes
parameters such as age at diagnosis, family history of prostate
cancer, ethnicity, PSA levels and survival data were collected, as
well as pathology reports, including Gleason scores. Survival data
was obtained through Cancer registry, which is maintained by
Cancer Council Queensland (last extraction-2016). The registry
operates under an Act of Parliament that requires mandatory
notification of all cancer cases in Queensland by all hospitals
(public, private, and psychiatric), nursing homes, and pathology
laboratories. Death certificates are accessed to identify if the cause
of death is cancer.
A total of 1,196 cancer-free control participants were included
in the study. None of the controls included had been diagnosed
with prostate cancer at the time of collection or presented
any symptoms. From these, 527 men recruited through the
Electoral Roll were age- and postal code-matched to patients
from the ProsCan study. A further 669 male controls were
recruited through the Australian Red Cross Blood Services.
All cancer-free volunteers completed a detailed questionnaire
that included information such as age, height and weight at
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the time of recruitment, and it also included risk factors and
sociodemographic variables like family history of prostate cancer,
whether they have had a vasectomy, as well as epidemiological
factors such as, smoking, drinking and education. The scale used
for all the variables are summarized in Table 1. All cases and
controls were of European ancestry. This study was approved
by the Queensland University of Technology’s Human Ethics
Committee (Ethics’ Approval Number: 1000001171), and all
participants provided informed written consent to participate in
prostate cancer genetic studies.
Genomic DNA Extraction and STR
Genotyping
White blood cells were obtained from 10 ml of venous blood that
were collected in EDTA tubes. Buffy coat was separated within
24 h and stored at −20◦C until further processing. Genomic
DNA was extracted from the buffy coats using the QIAamp
DNA Mini Kit as per the manufacturer’s instructions (Qiagen,
Hilden, Germany) as described previously (Batra et al., 2011b;
Lose et al., 2012) and a multiplex PCR was performed in a 96
well plates. Briefly, the multiplex PCR kit (QIAGEN, Chadstone,
VIC, Australia) was used in a 40 cycles’ PCR following the
manufacturer’s guidelines. NED-fluorescently labeled primers
(forward: 5′-GAGAAATGGCACAAAAACAGG-3′ and reverse:
5′-TTCTGTCAAGGTAATATTGCCAA-3′) were obtained from
Sigma-Aldrich (Castle Hill, NSW, Australia). The primers
were designed to amplify the STRs’ region at chromosome
8:126450287–126450311 position with a predicted product length
of 299 bp (according to UCSC hg19). A total of thirty-one 96 well
plates were subsequently analyzed according to their fragment
sizes by capillary electrophoresis using the 3500 Genetic Analyzer
platform (Applied Biosystems). Every plate had a well with water
as a blank to determine the specificity of our PCR product and a
total of 175 technical replicates were included across the plates to
determine the reproducibility of the results. Technical replicates
had to match in at least 90% of the hits detected to confirm
the robustness of the assay. Due to the nature of the amplified
and genotyped product, a 10% failure was allowed for potential
mistakes at the PCR and/or genotypic levels. The results were
then analyzed with GeneMapper v.5.0 (Thermo Fisher Scientific,
Waltham, MA, United States).
TTTTG-TRIB1 RT-qPCR
The APCB prostate tumor bank provided formalin fixed and
paraffin embedded (FFPE) blocks of prostate tissue, which
contained both prostate tumor and adjacent non-tumor cells.
The blocks were then sectioned sequentially in 20 µm sections
and placed on glass slides which were methyl green stained. The
pathologist marked tumor areas with their respective Gleason
scores (Supplementary Table 1). mRNA was isolated using
the RNeasy FFPE Kit (QIAGEN, Chadstone, VIC, Australia),
mRNA was reversed transcribed (RT) using Superscript III (Life
Technologies, Scoresby, VIC, Australia) as previously described
(Lai et al., 2017). RNA purity and quantity were analyzed
using the nanodropTM 2000/2000c Spectrophotometers and
quantitative PCR (RT-qPCR) was performed using the SYBR




(n = 1152) n (%)
Healthy controls
(n = 1196) n (%)
P-values
Age in years (mean,
range)
63.1 (40.2–87.1) 60.3 (18–89.6) P < 0.0001c
BMI (mean, SD) 28.4 (4.7) 27.9 (4.5) P = 0.091c
Marital status
Never married 14 (1) 8 (1)
Married/de facto 423 (37) 113 (9)
Divorced/separated/
widowed
44 (4) 13 (1) P > 0.9c
Unknown 672 (58) 1063 (89)
Family history of prostate cancera
No 498 (43) 796 (66.5)
Yes 263 (23) 94 (8) P > 0.9d
Unknown 392 (34) 306 (26)
Vasectomy statusb
No 286 (25) 699 (58)
Yes 148 (13) 445 (37) P > 0.9d
Unknown 718 (62) 52 (4)
Smoking status
Never smoked 426 (37) 496 (41)
Former smoker 582 (50.5) 580 (48.5) P > 0.9c
Current smoker 78 (7) 83 (7)
Unknown 67 (6) 37 (3)
Alcohol consumptionb
Non-drinker 63 (5.5) 143 (12) P > 0.9d
Drinker 370 (32) 1015 (85)
Unknown 719 (62) 38 (3)
Highest education level achieved
No formal
education
10 (1) 15 (1)
Primary/Secondary
school
516 (45) 469 (39) P > 0.9c
Professional
qualification
351 (30) 372 (31)
University degree 211 (18) 304 (25)
Unknown 62 (5) 37 (3)
Gleason score (Gleason grade 1 + Gleason grade 2)
<7 198 (17) Not applicable
≥7 785 (68) Not applicable
Unknown 171 (15) Not applicable
apositive family history is defined as at least one first degree relative with prostate
cancer. bdata was not collected for the retrospective study. cP-values are from
non-Parametric t-tests. dTwo-way ANOVA tests. body mass index (BMI) calculated
as: kg/m2.
Green method (Life Technologies, Scoresby, VIC, Australia).
Twenty available patients’ tumor and adjacent non-tumor
prostate tissue were selected based on their genotype as follows:
3/3 repeats (n = 2), 3/4 repeats (n = 8), and 4/4 repeats
(n = 10). Their Gleason grades are detailed in Supplementary
Table 1. The sequence at chr8:126450219-126450357 (UCSC
hg19) was amplified with a predicted PCR product length of
139 bp using the forward, 5′-GAATGCCGTGTATACCTCACG-
3′, and reverse, 5′-CGCAGGTTATTCAGACAGACA-3′ primers
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set. Applying the geometrical mean (geomean) of multiple
housekeeping genes in RT-qPCR assists in removing non-specific
gene variation expression, minimizing differences in the samples
gene expression detection due to variables such as the RNA
quantity and quality (Vandesompele et al., 2002). We therefore
used geomean of the two control genes as reference, HPRT1 and
RPL32. We then proceeded to evaluate the STR expression by
calculating the 1CT values = Ct TRIB1 – Ct Geomean of HPRT1
and RPL32.
Statistical Analysis
After checking if age and body mass index (BMI) followed
a Gaussian distribution, they were analyzed using a non-
parametric, unpaired t-test (GraphPad Prism 7.00). For other
parameters such as smoking, drinking, and marital status,
their frequencies in both cases and controls were calculated
and analyzed using a paired, non-parametric t-test. For those
parameters where only two pairs of values were available such
as family history, alcohol consumption and vasectomy status, a
two-way ANOVA test was used. To test if the STR was within
Hardy–Weinberg equilibrium (HWE), a chi-square test with a
confidence level of 0.05 was used (Hwe, 2016). STR genotype
and allele association with prostate cancer risk and aggressiveness
analysis were performed using binary logistic regression and
the odds ratios (ORs) were estimated as follows. For the allele
analysis, the dependent variable was the prostate cancer status
and the categorical covariate was the allele. In this analysis
no reference was used as the covariate variable was either
presence/absence of the allele (equal to 1 or 0, respectively). For
the genotype analysis, the dependent variable was the prostate
cancer status and the covariate variable was the genotypes. In
here, the analysis used the major allele (4/4) as the reference.
To verify that age was not biasing the results, a re-analysis was
performed using the allele/genotype as the categorical covariate
again, age as the second covariate and case-control status or
Gleason score as the dependent variables. All tests were repeated
using random sampling with replacement by bootstrapping
analysis. The tests were seeded 1,000,000 times in 1,000 samples.
Next, we analyzed the association of TTTTG-TRIB1 STR with
prostate cancer aggressiveness. A Gleason score of 8 and above
is associated with a poorly differentiated or high-grade disease
(Association of Directors of Anatomic and Surgical Pathology,
2018). We then grouped patients with a Gleason score of less than
8 and equal or greater than 8. Furthermore, since it has also been
reported that the Gleason score pattern for a Gleason score of 7
can be an informative prognostic tool (Stark et al., 2009), where
a higher primary Gleason score predicts a more lethal form of
the disease, we then subdivided into 3+4 and 4+3 patients with
a Gleason score = 7. Survival analysis was undertaken using the
Kaplan Meier test [Log-Rank (Mantel-Cox)]. Data was plotted
using GraphPad Prism 7.00. Hazard ratios (HR) were calculated
using the Cox-Regression analysis for both total and prostate
cancer related mortality. In this case the analysis was adjusted for
age, Gleason score and PSA values. All analyses were conducted
using IBM SPSS Statistics; 23.0 unless stated otherwise.
Differential TRIB1 expression in prostate cancer tissue and
adjacent normal tissue and correlation of genotype and allele data
with STR mRNA levels were analyzed using the non-parametric
Mann–Whitney test and plotted using GraphPad Prism 7.00.




In order to assess the potential impact that the two most
common alleles of TTTTG-TRIB1 have on the TRIB1 mRNA
folding structure, the in silico RNA folding predictor tool,
mfold web server v.31, was used (Zuker, 2003). There are two
transcript variants of TRIB1 according to the RefSeq genes
data set: transcript variant 1, NM_025195.3, and transcript
variant 2, NM_025195.1. Both were analyzed with the two
most common alleles, three- and four-TTTTG-TRIB1 repeats.
Since mfold calculates the most energetic favorable secondary
structures that compose a mRNA molecule (given by their
minimum free energy thermodynamic parameter, 1G◦), we
hypothesized that the alleles may have an effect in the final
folded structure and, potentially, in the final stability of
the molecule, affecting the functionality and/or levels of the
translated protein.
The Ingenuity Pathway Analysis (IPA; QIAGEN, Redwood
City, CA, United States) was used to identify a list of miRNAs
that bind to TRIB1 and are deregulated in prostate cancer. From
these, we sought for further confirmation in the miRNet database
(Fan et al., 2016). Next, microRNA.org was used to find predicted
miRNAs to bind near the STR (Betel et al., 2008). Finally,
RNAhybrid (Rehmsmeier et al., 2004) was applied to detect if the
miRNAs’ seed region of any of these miRNAs was altered by the
allele change.
RESULTS
TRIB1 Is Highly Expressed in Prostate
Cancer
Oncomine analysis (www.oncomine.org (Rhodes et al., 2004))
revealed TRIB1 is highly expressed in prostate cancer when
compared to other types of cancers in two multi-cancer clinical
datasets, suggesting a specific role of TRIB1 in this particular
disease. Su et al. (2001) showed an overexpression (Figure 1A)
in prostate cancer tissue when compared to bladder, breast,
colorectal, kidney, liver, lung, ovarian, and pancreatic cancers
(n = 174). Additionally, Ramaswamy et al. (2003) reported
TRIB1 to be overexpressed in prostate tumor tissue when
compared to breast, colorectal, lung and ovarian cancer tissues
(n = 76; Figure 1B). Furthermore, two independent data sets
also showed an increase of mRNA expression in prostate cancer
when compared to adjacent cancer-free tissue (Figures 1C,D; Liu
et al., 2006; Grasso et al., 2012, respectively), which suggests that
TRIB1 may be associated with prostate cancer initiation and/or
development.
1http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form2.3
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Demographic and Clinical
Characteristics of the Cohort
Epidemiological data is shown in Table 1. The socio-
demographic and clinical characteristics analysis showed
no significant differences between cases and controls for all of
the parameters analyzed (Table 1). Therefore, these parameters
were not used further. Only the mean of the age was significantly
different between the two groups (P < 0.05). This was expected
due to the nature of the recruitment of some healthy controls,
where samples from random blood donors were collected and
some were younger participants than the patient cohort.
The TTTTG-TRIB1 STR Is Associated
With Prostate Cancer Risk but Not With
Aggressiveness
In some instances, one of the technical replicates failed, either due
to amplification and/or electrophoresis issues. Of the genotyped
duplicates, 92% showed concordant results, satisfying the quality
control criteria of STR genotyping. We then proceed to analyze
our STR genotyping results. Three alleles were observed for the
TTTTG-TRIB1 STR, varying from three- to five-repeats. All
alleles were in HWE (P = 0.51). The three-repeat allele was
associated with prostate cancer risk at the allelic (OR = 1.16;
95%; CI = 1–1.34; P = 0.044) and genotypic levels (OR = 1.70;
95% CI = 1.16–2.49; P = 0.006; Table 2). The four-repeat allele
inversely associated with risk of prostate cancer at the allele level
(OR = 0.57; 95% CI = 0.44–0.75; P < 0.0001; Table 2). Similar
results were obtained after age adjusting and bootstrap reanalysis
(Table 2). The rest of the genotypes (3/5, 4/5, and 5/5) were not
analyzed due to the low number of observations (<1%).
No significant association betweeen the genotypes and
Gleason scores was obseved (P > 0.05; Supplementary Table 2),
suggesting the TTTTG-TRIB1 STR alleles have no effect in the
disease’s aggressiveness.
A total of 67 deaths were reported from the total cohort
of 1,152 patients, of which 25 were prostate cancer-related.
No significant differences in mortality were observed between
the 3/3, 3/4, and 4/4 TTTTG-TRIB1 genotypes etiher for total
mortality data [Log-Rank(Mantel-Cox) P = 0.695; Figure 2A]
or prostate cancer related deaths [Log-Rank (Mantel-Cox)
P = 0.466; Figure 2B] and these results were not affected by age,
Gleason scores and PSA values (HR and their respective P-values
are in Figure 2). Those patients with 5 TTTTG-TRIB1 repeats
(3/5, 4/5, and 5/5) were not included in the analysis due to their
low incidence (n = 1, 3 and 7, respectively).
TRIB1 mRNA Expression Is Not
Associated With the STR Allele
The TRIB1 gene expression showed a higher expression in
prostate cancer tumor when compared to adjacent non-
malignant tissue (P = 0.0005; Figure 3A). To identify if the STR
alleles regulate TR1BI expression in tumor tissue, we analyzed the
patient’s RNA from genotype two groups, i.e., carrying the three
repeats allele or carrying the four repeats allele. No allele and
TR1B1 mRNA expression correlation was observed either in the
tumor (Figure 3B) or in the adjacent benign tissue (Figure 3C).
TTTTG-TRIB1 Alleles May Alter the
mRNA Secondary Structure
From the 45–50 mRNA folded structures predicted by the
in silico mfold tool, we focused on the top ten most energetically
favorable ones, and compared how the change from three-
to four-TTTTG repeats affected the structures of the two
TRIB1 transcripts mentioned before. Four mRNA structures
from the top ten were different as a consequence of the
allelic change in the TRIB1 transcript variant 1 (NM_025195.3;
example shown in Figures 4A,B). When the TRIB1 transcript
variant 2 (NM_025195.1) was analyzed, there were eight mRNA
predicted structures from the top ten that were different
as a consequence of the allelic modification, including the
most favorable structure (Figures 4C,D). This suggests the
TTTTG-TRIB1 alleles influence the mRNA folding structure and
potentially this could also have an impact in the expression of the
translated protein, which could explain the differences in prostate
cancer risk observed in this study.
TABLE 2 | Allele and genotype risk association analysis of TTTTG-TRIB1 STR with prostate cancer risk.
Genotype Cases (%) Controls (%) OR (95%CI)a P-valuea OR (95% CI)b P-valueb P-valuec P-valued
3/3 74 (6) 47 (4) 1.70 (1.16–2.49) 0.006 1.65 (1.12–2.44) 0.011 0.006 0.01
3/4 365 (32) 384 (31) 1.03 (0.86–1.23) 0.75 – – – –
3/5 1 (0.1) 0 – – – – – –
4/4 701 (61) 759 (63) 1 – – – –
4/5 9 (0.7) 9 (0.7) – – – – – –
5/5 2 (0.2) 0 – – – – – –
Allele
3 514 (22) 478 (20) 1.16 (1.00–1.34) 0.044 1.18 (1.01–1.36) 0.03 0.044 0.031
4 1776 (77) 1911 (80) 0.57 (0.44–0.75) <0.0001 0.59 (0.45–0.77) <0.0001 0.001 0.001
5 14 (0.6) 9 (0.4) – – – – – –
Calculated using abinary Logistic Regression, where the dependant variable is the case-control status and the covariate is the allele/genotypebage adjusted binary logistic
regression, where age is the second covariate cbootstrap (two-tailed) and dbootstrap (two-tailed) age adjusted. (IBM SPSS Statistic Processor; 23). CI, confidence
interval; OR, odds ratio.
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FIGURE 2 | Survival data analysis. (A) Total mortality data [Log-Rank (Mantel-Cox) P-value = 0.16], (B) prostate cancer mortality data [Log-Rank (Mantel-Cox)
P-value = 0.43] where TTTTG-TRIB1 genotypes (3/3, 3/4, 4/4) are represented as a function of percentage survival over 125 months. HR and P-values were
calculated using Cox-Regression analysis and adjusted for age, Gleason score and PSA values. HR, hazard ratio; CI, confidence interval.
FIGURE 3 | RT-qPCR from twenty patient tissue samples for TTTTG-TRIB1. Expression of the (A) TRIB1 gene in tumor tissues when compared to adjacent
non-malignant tissues and expression of the 3- and 4-repeats alleles in (B) tumor tissues and (C) adjacent non-malignant tissues. ∗∗∗P = 0.0005, value calculated
using the Mann–Whitney test (GraphPad Prism 7.00).
Since the TTTTG-TRIB1 STR is within the 3′UTR, we
investigated if the alleles have an effect in regulating the TRIB1
gene expression by affecting the miRNA binding site region and
interfering in the miRNA–mRNA duplex formation. The alleles
of the TTTTG-TRIB1 STR were not predicted to have an effect
on any of the analyzed miRNAs binding.
DISCUSSION
Short tandem repeats are attractive biomarkers in human disease
due to their highly polymorphic nature, abundancy and wide
distribution throughout the genome (Schlotterer, 2004; Willems
et al., 2014). They have been used for linkage mapping in several
organisms, including humans (Weissenbach et al., 1992) and
they have been associated with genetically simple and complex
human diseases (Hefferon et al., 2004; Willems et al., 2014),
including neurological disorders (Brouwer et al., 2009). A recent
publication has shown massive STR sequencing (STR-Seq) is
possible using the CRISPR-Cas9 technology (Shin et al., 2017).
This study, published after our analysis was done, not only
highlights the power of STRs as tools for genetic diagnosis, but
it also shows the on-going interest of pursuing the sequencing
of STRs for genetic association studies. However, this novel STR-
Seq approach may not always be suitable to implement as it may
depend on the resources available. In this study, we used a pre-
screening approach where existing databases and bioinformatics
tools were applied to detect STRs within differentially expressed
genes in prostate cancer as shown in our recent publication
(Lai et al., 2017). Using such methodology, we identified a
penta-STR within the 3′UTR of the TRIB1 gene: TTTTG. This
gene is part of the tribbles family, comprised of three genes:
TRIB1, TRIB2, and TRIB3. It is a highly conserved pseudokinase
(Yokoyama and Nakamura, 2011) that lacks the protein-to-
protein interaction domains and possibly any catalytic activity
(Wei et al., 2012). Instead of directly phosphorylating proteins,
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FIGURE 4 | Predicted secondary structures of the two TRIB1 mRNA transcripts. Showing two examples of the differences observed in the predicted TRIB1 mRNA
structure of the TRIB1 transcript variant one with the three (A) and four (B) TTTTG-TRIB1 repeats alleles; and of the TRIB1 transcript variant two with the three (C)
and four (D) TTTTG-TRIB1 repeats alleles. The dotted squares highlight the secondary structures differences in the final structure. Data obtained from mfold web
server v.3 (http://www.bioinfo.rpi.edu/applications/mfold.).
this family of genes acts as an adaptor protein that regulates
several cell pathways by enabling the degradation of targeted
proteins after interacting with different cell mediators (Wei et al.,
2012; Dugast et al., 2013). Intracellularly, TRIB1 has an important
role of regulating the C/EBP family of transcription factors
(Yokoyama and Nakamura, 2011), responsible of processes such
as transcription/translation and isoform formation (Hattori et al.,
2003). TRIB1 is also a known regulator of the mitogen-activated
protein kinase (MAPK) pathway (Sung et al., 2007; Yokoyama
and Nakamura, 2011), which activates/inhibits key cell processes
such as growth, proliferation, differentiation, migration, and
apoptosis, all of which have a pivotal role in cancer development
and progression (Dhillon et al., 2007; Roberts and Der, 2007). In
fact, TRIB1 has been described as a myeloid oncogene due to its
strong link with leukemia (Rothlisberger et al., 2007; Yokoyama
and Nakamura, 2011). In a previously mentioned recent study,
the TRIB1 gene has also shown to play a significant role in
prostate cancer, where its knockdown decreased the proliferation
and survival of prostate cancer cells in a three-dimensional
in vitro model, as well as it promoted prostate tumorigenesis in
an in vivo xenograft model after gene over-expression (Mashima
et al., 2014). The increase in prostate tumor growth observed was
reversed in a TRIB1 knockdown model. In addition, TRIB1 has
also been shown to be downregulated by androgens in LNCaP
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prostate cancer cells (Munkley et al., 2015; Lai et al., 2017).
Since androgens are a key signaling molecule in prostate cancer
development and the main current therapeutic target (androgen
deprivation therapy), this suggests TRIB1 plays a role in the onset
and/or development of the disease. It is not surprising then that
the publicly available database Oncomine (Rhodes et al., 2004),
revealed numerous independent clinical datasets that showed
an overexpression of this gene in prostate cancer tissue when
compared to adjacent cancer-free cells (LaTulippe et al., 2002;
Varambally et al., 2005; Liu et al., 2006; Taylor et al., 2010; Grasso
et al., 2012). Interestingly, Oncomine analysis also showed that
TRIB1 is highly expressed in prostate cancer when compared to
other types of cancers in two independent multi-cancer studies
(Su et al., 2001; Ramaswamy et al., 2003, respectively). All this
evidence supports a role of TRIB1 in the onset and/or progression
of the disease.
In this study, we genotyped over 2,000 patients and matching
controls for the TTTTG-TRIB1 STR and found three alleles
(three, four, and five repeats) in this population. The three-repeat
allele showed a prostate cancer risk association at both the allele
(P = 0.044) and genotype levels (P = 0.006) and this was stronger
in the genotype analysis (OR = 1.16 vs. OR = 1.70). This difference
could be due to a synergistic effect of the two alleles when
combined. This study also showed that the allele/genotype does
not affect the disease aggressiveness. Both results showed not to
be associated with age after being age-adjusted. Additionally, no
association with prostate cancer survival was observed, possibly
due to the low number of reported deaths in our data set.
Further follow ups, where more prostate cancer related deaths
may be reported, could elucidate the role of this STR as a
prognostic tool if such role indeed exists. We did not observe age,
Gleason score or PSA had an effect on survival analysis in our
cohort despite Gleason scores have previously shown to influence
the prognosis of prostate cancer patients (Wright et al., 2009).
Although not significant, an opposite effect of the 4/4 genotype
with survival compared to its risk association with prostate
cancer was observed. This could be due to the context dependent
function of these alleles in the tumor microenvironment of an
aggressive cancer vs. less aggressive tumor conditions, which
has also been reported in recent publications such as SNP
association studies (Wiklund et al., 2009; Pomerantz et al., 2010,
2011; Ahn et al., 2011). For example, a risk allele of the MSMB
gene has been reported to be associated with prostate cancer
compared to controls, but its association was stronger for non-
fatal prostate cancer. Furthermore, the frequency of the risk allele
was higher for non-fatal prostate cancer compared with fatal
prostate cancer, but it was also associated with a decreased rate of
progression to prostate cancer specific mortality (Wiklund et al.,
2009; Pomerantz et al., 2010). Ahn et al. (2011), also reported
that a risk allele in the MSMB and 8q24 genes were associated
with an increased risk of metastatic prostate cancer compared
with controls but not with time of recurrence in prostate cancer
cases following diagnosis. Therefore, the observation that that
the 4/4 genotype individuals have poorer survival (although not
significant) and it is inversely associated with risk of prostate
cancer is not surprising. Another limitation of this study was that
our access to prostate tumor tissue and their adjacent non-tumor
cells was limited in number: n = 10 for the three-TTTTG repeats
and n = 18 for the four-TTTTG repeats allele, and therefore
the results should be read with caution. This could explain why
no significant differences in allele specific mRNA expression
were observed. Future analysis, where additional samples can be
included may clarify if the TRIB1 expression in prostate tumor
tissue contributes to a poorer survival outcome as recently shown
in a breast cancer study (Gendelman et al., 2017).
Since this STR is in the 3′UTR and its two most common
alleles, three- and four-TTTTG repeats, have a difference of five
nucleotides, we hypothesized this could affect either the miRNAs
binding site or the final mRNA folding, and therefore have an
effect in the stability and translation of the protein, potentially
affecting the TRIB1 protein levels. Our miRNA analysis showed
no differences in the 3′ UTR seed region when changing the STR
allele from three- to four-repeats, suggesting the risk differences
observed in this study are due to other regulatory mechanisms.
Alternatively, there could be one or more miRNAs not yet
identified that are affected by the polymorphism of the STR.
We then focused on how the alleles could affect the TRIB1
mRNA structure. The predictor tool, mfold v3.0, showed the
TTTTG-TRIB1 alleles altered not only the order in which a given
structure was most favorable but they also promoted unique
structures for the two known TRIB1 transcripts. It would be
interesting to investigate further the role of these two transcripts
in prostate cancer development and if the TTTTG-TRIB1 STR
found herein has indeed an effect on TRIB1 mRNA stability,
by possibly promoting or interfering in the translation of the
mRNA. However, it is important to note that the minimum
free energy method used by the mfold predictor tool has its
own limitations such as assuming the RNA molecule is in
equilibrium, that it has a single conformation and the nearest-
neighbor effects are non-existent (Mathews, 2015). For these
reasons, additional computational methods should be used to
confirm the physiological significance of these findings and they
also need to be experimentally validated by analyzing the allele
specific protein expression of the TR1BI with a recently validated
antibody (Soubeyrand et al., 2017). Finally, although we identified
the TR1B1 STR through a method completely independent of
GWAS, and for the first time analyzed the association of a
polymorphism within the TRIB1 gene, it must be mentioned that
several SNPs associated with prostate cancer have been detected
by GWAS in the same locus than the TRIB1 gene (Gudmundsson
et al., 2007, 2012; Srinivasan et al., 2016). It would therefore
be imperative to establish the TR1B1 STR as an independent
marker to GWAS identified SNPs at 8q24 for prostate cancer by
undertaking the regression analysis conditioned on the GWAS
loci.
In summary, the TRIB1 gene is significantly overexpressed
in prostate cancer when compared to other types of cancer and
it is upregulated in prostate tumor tissue when compared to
adjacent cancer-free cells. After genotyping over 2,000 prostate
cancer patients and controls, we found the TTTTG-TRIB1 STR
is polymorphic and its three repeats allele has an association
with prostate cancer risk at both the allelic and genotypic levels.
However, no associations with mortality or aggressive disease
were found. Further association studies in a larger cohort are
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warranted to confirm the outcome of our study. Our in silico
predictions indicated that the TRIB1 mRNA structures are allele
dependent. This repeat length could be affecting the mRNA
stability and hence their expression level. Additional mechanisms
by which this STR regulates TRIB1 expression in an allele specific
manner need to be further explored. Collectively, these findings
validate our biomarker discovery approach methodology and
highlight the utility of pursuing the use of STRs as biomarkers.
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